• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 3. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 4. Etching of glass microchips with supercritical water?
  Pavel Karásek,Jakub Grym,Michal Roth,Josef Planeta,Franti?ek Foret Lab Chip, 2015,15, 311-318
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

Recent Advances in the Study of 3-(4-ethoxyphenyl)-2-oxopropanoic acid (CAS: 175897-64-0): A Comprehensive Research Brief

3-(4-ethoxyphenyl)-2-oxopropanoic acid (CAS: 175897-64-0) has recently garnered significant attention in the chemical biology and pharmaceutical research communities due to its potential therapeutic applications and unique biochemical properties. This compound, characterized by its ethoxyphenyl and oxopropanoic acid functional groups, has been the subject of several cutting-edge studies aimed at elucidating its mechanism of action, pharmacokinetics, and potential clinical uses. The following research brief synthesizes the latest findings related to this compound, providing a comprehensive overview for professionals in the field.

Recent studies have focused on the synthesis and optimization of 3-(4-ethoxyphenyl)-2-oxopropanoic acid, with particular emphasis on improving its yield and purity. A 2023 publication in the Journal of Medicinal Chemistry detailed a novel synthetic route that utilizes palladium-catalyzed cross-coupling reactions, achieving a 78% yield with high enantiomeric purity. This advancement is critical for scaling up production for preclinical and clinical studies. Additionally, researchers have explored the compound's stability under various physiological conditions, revealing its relative stability in acidic environments but susceptibility to hydrolysis at elevated pH levels.

The pharmacological profile of 3-(4-ethoxyphenyl)-2-oxopropanoic acid has been extensively investigated in recent in vitro and in vivo studies. A pivotal study published in Biochemical Pharmacology demonstrated its potent inhibitory effects on key inflammatory mediators, including COX-2 and TNF-α, suggesting potential applications in treating chronic inflammatory diseases. Furthermore, molecular docking simulations have identified strong interactions between the compound and the active sites of these enzymes, providing a structural basis for its bioactivity. These findings position 3-(4-ethoxyphenyl)-2-oxopropanoic acid as a promising lead compound for the development of novel anti-inflammatory agents.

In the realm of metabolic disorders, 3-(4-ethoxyphenyl)-2-oxopropanoic acid has shown remarkable potential as a modulator of glucose metabolism. A 2024 study in Diabetes & Metabolism highlighted its ability to enhance insulin sensitivity in adipocytes through the activation of AMPK pathways. Animal models of type 2 diabetes treated with the compound exhibited significant improvements in glycemic control and lipid profiles, with no observed hepatotoxicity at therapeutic doses. These results underscore its viability as a candidate for antidiabetic drug development, though further pharmacokinetic studies are warranted to optimize dosing regimens.

Beyond its therapeutic potential, recent research has also explored the compound's utility as a chemical probe in biological systems. Its fluorescent properties, when derivatized with specific moieties, have enabled real-time tracking of cellular uptake and distribution in various tissue types. This application was detailed in a recent ACS Chemical Biology publication, where researchers utilized the compound to study drug penetration across the blood-brain barrier, yielding valuable insights for central nervous system drug development.

Despite these promising developments, challenges remain in the clinical translation of 3-(4-ethoxyphenyl)-2-oxopropanoic acid. Current research gaps include comprehensive toxicology profiles in higher mammalian species and long-term stability studies of formulated products. However, the collective findings from recent studies provide a strong foundation for continued investigation and potential commercialization of this versatile compound in the pharmaceutical industry.

• 28030-16-2(3-(4-methoxyphenyl)-2-oxopropanoic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)